Literature DB >> 22371126

In the cystoscopic follow-up of non-muscle-invasive transitional cell carcinoma, NMP-22 works for high grades, but unreliable in low grades and upper urinary tract tumors.

Enis Coskuner1, Ibrahim Cevik, Alp Ozkan, Ozdal Dillioglugil, Atıf Akdas.   

Abstract

INTRODUCTION AND
OBJECTIVES: Two percent of the bladder non-muscle-invasive (NMI) transitional cell carcinomas (TCC) are associated with upper urinary tract (UUT) TCC. We evaluated the role of nuclear matrix protein-22 (NMP-22) (BladderChek) test in the diagnosis of lower urinary tract and UUT-TCC.
METHODS: From March 2009 to June 2011, 122 patients with bladder NMI-TCC underwent 205 control cystoscopy. A total of 95 (78 men and 17 women, mean age 60.7 years, range, 27-88) patients who were followed regularly with NMP-22 test and with follow-up cystoscopies (145 episodes; min. 1-max. 5) were included in this study. For routine monitoring of the UUT, IVU or CT urography was used once a year for high grades (HG), and once in every other year for low grades (LG). The sensitivity and specificity of NMP-22 were evaluated by ROC curves, and sensitivity, specificity, and positive and negative predictive values were calculated. Chi-square test was used for the differences between the subgroups.
RESULTS: Cystoscopy and NMP-22 results of the patients included in the study revealed the sensitivity (44.4%) of the test was very low and the specificity (98.4%) was quite high (p < 0.001). Among the 10 cystoscopies where NMP-22 was negative, but cystoscopy was positive for tumor, 8 had LG and 2 had HG TCC. NMP-22 was never positive in low-grade tumors, in other words, all of the NMP-22-positive 8 tumors were high grade. On the other hand, in 20% (2/10) of the cases, NMP-22 can be negative although the tumor was high grade. Two (2.1%) HG UUT-TCC were detected in 95 patients. These 2 patients were within the 125 cystoscopies (75 patients) where both NMP-22 and cystoscopy were negative for tumor.
CONCLUSIONS: Nuclear matrix protein-22 cannot detect LG TCC. However, it detects overwhelming majority of HG TCC. For this reason, positive NMP-22 test largely indicates HG TCC. NMP-22 is also not reliable in UUT-TCC, even in HG tumors.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22371126     DOI: 10.1007/s11255-012-0144-x

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  34 in total

1.  Use of the NMP22 BladderChek test in the diagnosis and follow-up of urothelial cancer: a cross-sectional study.

Authors:  Eu Chang Hwang; Hyang Sik Choi; Seung Il Jung; Dong Deuk Kwon; Kwangsung Park; Soo Bang Ryu
Journal:  Urology       Date:  2010-08-24       Impact factor: 2.649

2.  Detection of bladder cancer using a point-of-care proteomic assay.

Authors:  H Barton Grossman; Edward Messing; Mark Soloway; Kevin Tomera; Giora Katz; Yitzhak Berger; Yu Shen
Journal:  JAMA       Date:  2005-02-16       Impact factor: 56.272

3.  Surveillance for recurrent bladder cancer using a point-of-care proteomic assay.

Authors:  H Barton Grossman; Mark Soloway; Edward Messing; Giora Katz; Barry Stein; Vahan Kassabian; Yu Shen
Journal:  JAMA       Date:  2006-01-18       Impact factor: 56.272

Review 4.  The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee.

Authors:  J I Epstein; M B Amin; V R Reuter; F K Mostofi
Journal:  Am J Surg Pathol       Date:  1998-12       Impact factor: 6.394

Review 5.  Urine markers for detection and surveillance of non-muscle-invasive bladder cancer.

Authors:  Derya Tilki; Maximilian Burger; Guido Dalbagni; H Barton Grossman; Oliver W Hakenberg; Juan Palou; Oliver Reich; Morgan Rouprêt; Shahrokh F Shariat; Alexandre R Zlotta
Journal:  Eur Urol       Date:  2011-06-12       Impact factor: 20.096

Review 6.  Urine markers for bladder cancer surveillance: a systematic review.

Authors:  Bas W G van Rhijn; Henk G van der Poel; Theo H van der Kwast
Journal:  Eur Urol       Date:  2005-03-23       Impact factor: 20.096

7.  Upper-tract tumors after an initial diagnosis of bladder cancer: argument for long-term surveillance.

Authors:  F Rabbani; M Perrotti; P Russo; H W Herr
Journal:  J Clin Oncol       Date:  2001-01-01       Impact factor: 44.544

Review 8.  Utilization of nuclear matrix proteins for cancer diagnosis.

Authors:  S K Keesee; J V Briggman; G Thill; Y J Wu
Journal:  Crit Rev Eukaryot Gene Expr       Date:  1996       Impact factor: 1.807

9.  Superficial bladder cancer: progression and recurrence.

Authors:  N M Heney; S Ahmed; M J Flanagan; W Frable; M P Corder; M D Hafermann; I R Hawkins
Journal:  J Urol       Date:  1983-12       Impact factor: 7.450

10.  Monitoring of the upper urinary tract in patients with bladder cancer.

Authors:  Rajinikanth Ayyathurai; Mark S Soloway
Journal:  Indian J Urol       Date:  2011-04
View more
  4 in total

Review 1.  Diagnostic challenges and treatment strategies in the management of upper-tract urothelial carcinoma.

Authors:  Victor M Schuettfort; Benjamin Pradere; Fahad Quhal; Hadi Mostafaei; Ekaterina Laukhtina; Keiichiro Mori; Reza Sari Motlagh; Michael Rink; David D'Andrea; Mohammad Abufaraj; Pierre I Karakiewicz; Shahrokh F Shariat
Journal:  Turk J Urol       Date:  2020-10-09

Review 2.  Novel non invasive diagnostic strategies in bladder cancer.

Authors:  Anamaria Truta; Tudor Adrian Hodor Popon; George Saraci; Liviu Ghervan; Ioan Victor Pop
Journal:  Clujul Med       Date:  2016-04-15

Review 3.  An up-to-date catalog of available urinary biomarkers for the surveillance of non-muscle invasive bladder cancer.

Authors:  Francesco Soria; Michael J Droller; Yair Lotan; Paolo Gontero; David D'Andrea; Kilian M Gust; Morgan Rouprêt; Marek Babjuk; Joan Palou; Shahrokh F Shariat
Journal:  World J Urol       Date:  2018-06-21       Impact factor: 4.226

4.  Evaluation of the NMP22 BladderChek test for detecting bladder cancer: a systematic review and meta-analysis.

Authors:  Zijie Wang; Hongliang Que; Chuanjian Suo; Zhijian Han; Jun Tao; Zhengkai Huang; Xiaobin Ju; Ruoyun Tan; Min Gu
Journal:  Oncotarget       Date:  2017-10-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.